New drug candidate AGSAVI aims to lower stubborn high blood pressure
NCT ID NCT05503953
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 study tests whether the drug AGSAVI can lower blood pressure in people with essential hypertension that is not well controlled by the drug AGLS. About 318 adults with high blood pressure will receive either AGSAVI or AGLS, and their sitting blood pressure will be measured over 10 weeks. The goal is to see if AGSAVI provides better blood pressure control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AGSAVI
- What this could lead to
- If successful, AGSAVI could offer a new treatment option for people with high blood pressure that is not well controlled by current medications.
- What could go wrong
- This is a phase 3 trial, but results may not confirm superiority or safety over existing treatments. Side effects are possible, and individual responses may vary.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESSENTIAL HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
AhnGook
Seoul, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a heart drug be a new key to controlling high blood pressure?
- A simple arm cuff may lower blood pressure without drugs
- AI tailors blood pressure drugs, outsmarting One-Size-Fits-All medicine
- Herbal capsule aims to tackle both high blood pressure and poor sleep
- New drug combo aims to tame stubborn high blood pressure
- New combo pill aims to tame stubborn high blood pressure